72
Korro Bio doses first cohort in Phase 1/2 trial of KRRO-121
Why it matters
Korro Bio announced first-in-human dosing of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide, in its ANCHOR Phase 1/2 trial for hyperammonemia and hepatic encephalopathy. Clinical trial initiation marks a material milestone for a lead program, signaling progress toward potential regulatory path and reducing development risk for the company.
In plain language
A biotech company just started testing its experimental drug in patients for the first time. This is a key step forward that can move the stock up if investors believe the drug has promise.
Exposure
KRRO ▲
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.